Literature DB >> 22139852

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Takami Sato1, Mizue Terai, Yutaka Tamura, Vitali Alexeev, Michael J Mastrangelo, Senthamil R Selvan.   

Abstract

IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex; however, the presence of IL-10 in advanced metastases and the positive correlation between serum IL-10 levels and progression of disease indicates a critical role of IL-10 in the tumor microenvironment. IL-10 has been shown to directly affect the function of antigen-presenting cells by inhibiting the expression of MHC and costimulatory molecules, which in turn induces immune suppression or tolerance. Additionally, IL-10 downregulates the expression of Th1 cytokines and induces T-regulatory responses. Taken together, a combination of IL-10 antagonism and immunostimulatory treatments such as cancer vaccines, Toll-like receptor agonists, Th1 cytokines, and chemokines would be a logical approach to enhance an antitumor immune response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139852     DOI: 10.1007/s12026-011-8262-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  106 in total

1.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.

Authors:  Abdelilah Wakkach; Nathalie Fournier; Valérie Brun; Jean-Philippe Breittmayer; Françoise Cottrez; Hervé Groux
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

2.  C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R.

Authors:  Carolyn Mold; Wilfredo Rodriguez; Bojana Rodic-Polic; Terry W Du Clos
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

3.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

4.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

Review 5.  Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response.

Authors:  Peter J Murray
Journal:  Curr Opin Pharmacol       Date:  2006-05-18       Impact factor: 5.547

6.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

7.  Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering.

Authors:  Alexander D Edwards; Shivanthi P Manickasingham; Roman Spörri; Sandra S Diebold; Oliver Schulz; Alan Sher; Tsuneyasu Kaisho; Shizuo Akira; Caetano Reis e Sousa
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Comparison of interleukin-22 and interleukin-10 soluble receptor complexes.

Authors:  Naomi J Logsdon; Brandi C Jones; Kristopher Josephson; Jennifer Cook; Mark R Walter
Journal:  J Interferon Cytokine Res       Date:  2002-11       Impact factor: 2.607

9.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Authors:  Alain P Vicari; Claudia Chiodoni; Céline Vaure; Smina Aït-Yahia; Christophe Dercamp; Fabien Matsos; Olivier Reynard; Catherine Taverne; Philippe Merle; Mario P Colombo; Anne O'Garra; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  85 in total

1.  High macrophage PD-L1 expression not responsible for T cell suppression.

Authors:  Naomi Goldman; Yelizavet D Lomakova; Jennifer Londregan; Amanda Bucknum; Kelley DePierri; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2017-12-30       Impact factor: 4.868

2.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

Review 3.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

4.  API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.

Authors:  Kyung Hee Noh; Seok-Ho Kim; Jin Hee Kim; Kwon-Ho Song; Young-Ho Lee; Tae Heung Kang; Hee Dong Han; Anil K Sood; Joanne Ng; Kwanghee Kim; Chung Hee Sonn; Vinay Kumar; Cassian Yee; Kyung-Mi Lee; Tae Woo Kim
Journal:  Cancer Res       Date:  2014-04-25       Impact factor: 12.701

5.  Oncolytic viruses: focusing on the tumor microenvironment.

Authors:  C R de Vries; H L Kaufman; E C Lattime
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

6.  Mimicking the tumor microenvironment to regulate macrophage phenotype and assessing chemotherapeutic efficacy in embedded cancer cell/macrophage spheroid models.

Authors:  Kristie M Tevis; Ryan J Cecchi; Yolonda L Colson; Mark W Grinstaff
Journal:  Acta Biomater       Date:  2016-12-21       Impact factor: 8.947

7.  Interleukin 10 promotes immune response by increasing the survival of activated CD8+ T cells in human papillomavirus 16-infected cervical cancer.

Authors:  Li Li; Yan Ma; Shuang Liu; Jin Zhang; Xin-Yan Xu
Journal:  Tumour Biol       Date:  2016-10-11

Review 8.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

9.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

10.  CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination.

Authors:  Andrea Mencarelli; Luigina Graziosi; Barbara Renga; Sabrina Cipriani; Claudio D'Amore; Daniela Francisci; Angela Bruno; Franco Baldelli; Annibale Donini; Stefano Fiorucci
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.